HER2+

Discover how advancements in HER2+ brain metastases treatment, including drugs like lapatinib, are changing the outlook for patients with CNS breast cancer.

If you’ve recently been diagnosed with early-stage HER2-positive breast cancer, you may be wondering what “HER2-positive” really means and how that influences treatment. HER2 is one of several important characteristics doctors look at when diagnosing breast cancer. Knowing whether your cancer is HER2-positive helps your care team understand how the cancer may behave and, importantly, […]

Treatment for HER2-positive early breast cancer has changed significantly over the past several decades. Today, HER2-targeted therapies are an important part of treatment for many people, helping improve outcomes for a cancer that was once much more difficult to treat. Researchers are asking an important next question: Can we make treatment more personalized? Rather than […]

If you’ve been diagnosed with HER2-positive early-stage breast cancer, you may have questions about what your HER2 status means and whether recent treatment advances could affect your care. In May 2026, the U.S. Food and Drug Administration (FDA) approved trastuzumab deruxtecan, or T-DXd (Enhertu), for two uses in HER2-positive early-stage breast cancer: before surgery for […]

If you’ve recently been diagnosed with breast cancer, you may have heard your doctor mention something called “HER2.” It can sound technical and overwhelming at first, but understanding HER2 is an important step in making sense of your diagnosis and treatment options. HER2 stands for human epidermal growth factor receptor 2. It’s a protein found […]

Integrative oncology for breast cancer: Managing HER2 treatment side effects If you’ve been diagnosed with HER2-positive breast cancer, your treatment plan may include therapies that specifically target the HER2 protein. While these treatments are effective, they can come with side effects that can be challenging to navigate. Integrative oncology can complement your treatment plan to […]

Recent advancements have brought attention to a specific group of breast cancers called “HER2-low.” These are tumors that have some HER2 protein on their surface (classified as HER2 1+ or HER2 2+ without gene amplification) but not enough to be considered HER2-positive. Enhertu (trastuzumab deruxtecan [T-DXd]), has shown significant positive results for patients with HER2-low […]

The power of exercise after HER2-positive breast cancer If you’ve been diagnosed with HER2-positive breast cancer, your treatment plan may include targeted therapies, chemotherapy, surgery, and/or radiation.  While these treatments are often effective, they may lead to side effects that take a toll on your quality of life. New data emphasizes the critical role of […]

What you should know about Enhertu We had the honor of hosting medical oncologist Dr. Heidi Ko in our recent “Ask the Expert” webinar to discuss how HER2 (human epidermal growth factor receptor 2) influences cancer care. In this educational discussion, Dr. Ko explores why testing for HER2 is significant, the treatment options available, and […]

Safety outcomes with first-line treatment of Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) plus Perjeta (pertuzumab) is comparable with that of standard of care treatment options in patients with HER2-positive advanced or metastatic breast cancer. These findings were derived from the phase 3 DESTINY-Breast09 trial which were shared at the 2025 ASCO Annual Meeting. The multicenter, open-label DESTINY-Breast09 […]

A recent study is aiming to understand and classify the HER2 protein levels in breast cancer, particularly those with early-stage, estrogen receptor-positive (ER-positive) breast cancer. The trial, which was a part of the 2025 American Society of Oncology (ASCO) Annual Meeting, suggests that by re-examining existing ways of interpreting HER2 levels, more patients may benefit […]

One of the most important first steps after receiving a breast cancer diagnosis is understanding one’s specific type of cancer. Recently, exciting new tools are emerging that can make this process even better: artificial intelligence (AI). In a study presented at the 2025 American Society of Oncology (ASCO) Annual Meeting by Dr. Marina De Brot, […]